Logo image of IMMX

IMMIX BIOPHARMA INC (IMMX) Stock Fundamental Analysis

USA - NASDAQ:IMMX - US45258H1068 - Common Stock

4.21 USD
+0.6 (+16.62%)
Last: 11/14/2025, 8:00:01 PM
4.2999 USD
+0.09 (+2.14%)
After Hours: 11/14/2025, 8:00:01 PM
Fundamental Rating

2

Overall IMMX gets a fundamental rating of 2 out of 10. We evaluated IMMX against 533 industry peers in the Biotechnology industry. The financial health of IMMX is average, but there are quite some concerns on its profitability. IMMX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMMX has reported negative net income.
IMMX had a negative operating cash flow in the past year.
In the past 5 years IMMX always reported negative net income.
In the past 5 years IMMX always reported negative operating cash flow.
IMMX Yearly Net Income VS EBIT VS OCF VS FCFIMMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -147.91%, IMMX is not doing good in the industry: 84.93% of the companies in the same industry are doing better.
IMMX's Return On Equity of -497.03% is on the low side compared to the rest of the industry. IMMX is outperformed by 77.02% of its industry peers.
Industry RankSector Rank
ROA -147.91%
ROE -497.03%
ROIC N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMMX Yearly ROA, ROE, ROICIMMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMMX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMX Yearly Profit, Operating, Gross MarginsIMMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, IMMX has more shares outstanding
Compared to 5 years ago, IMMX has more shares outstanding
IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMMX Yearly Shares OutstandingIMMX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IMMX Yearly Total Debt VS Total AssetsIMMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -5.05, we must say that IMMX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IMMX (-5.05) is worse than 60.08% of its industry peers.
There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.05
ROIC/WACCN/A
WACCN/A
IMMX Yearly LT Debt VS Equity VS FCFIMMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.23 indicates that IMMX should not have too much problems paying its short term obligations.
IMMX has a worse Current ratio (1.23) than 85.88% of its industry peers.
A Quick Ratio of 1.23 indicates that IMMX should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.23, IMMX is not doing good in the industry: 85.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
IMMX Yearly Current Assets VS Current LiabilitesIMMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

IMMX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.27%.
EPS 1Y (TTM)7.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMMX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.14% yearly.
Based on estimates for the next years, IMMX will show a very strong growth in Revenue. The Revenue will grow by 155.56% on average per year.
EPS Next Y8.54%
EPS Next 2Y-1.15%
EPS Next 3Y46.2%
EPS Next 5Y48.14%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y223.96%
Revenue Next 5Y155.56%

3.3 Evolution

IMMX Yearly Revenue VS EstimatesIMMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2027 2028 2029 2030 2031 50M 100M 150M
IMMX Yearly EPS VS EstimatesIMMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IMMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMX Price Earnings VS Forward Price EarningsIMMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMX Per share dataIMMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as IMMX's earnings are expected to grow with 46.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.15%
EPS Next 3Y46.2%

More info and screens

0

5. Dividend

5.1 Amount

IMMX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMIX BIOPHARMA INC

NASDAQ:IMMX (11/14/2025, 8:00:01 PM)

After market: 4.2999 +0.09 (+2.14%)

4.21

+0.6 (+16.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-23 2026-03-23/amc
Inst Owners8.46%
Inst Owner Change22.18%
Ins Owners24.49%
Ins Owner Change0.05%
Market Cap137.54M
Revenue(TTM)N/A
Net Income(TTM)-23.13M
Analysts82.86
Price Target8.16 (93.82%)
Short Float %2.85%
Short Ratio1.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.63%
Min EPS beat(2)-34.8%
Max EPS beat(2)36.06%
EPS beat(4)2
Avg EPS beat(4)-2.14%
Min EPS beat(4)-47.06%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 29.56
P/tB 29.56
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -147.91%
ROE -497.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1196.56%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -5.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
EPS Next Y8.54%
EPS Next 2Y-1.15%
EPS Next 3Y46.2%
EPS Next 5Y48.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y223.96%
Revenue Next 5Y155.56%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.91%
OCF growth 3YN/A
OCF growth 5YN/A

IMMIX BIOPHARMA INC / IMMX FAQ

What is the fundamental rating for IMMX stock?

ChartMill assigns a fundamental rating of 2 / 10 to IMMX.


Can you provide the valuation status for IMMIX BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to IMMIX BIOPHARMA INC (IMMX). This can be considered as Overvalued.


How profitable is IMMIX BIOPHARMA INC (IMMX) stock?

IMMIX BIOPHARMA INC (IMMX) has a profitability rating of 0 / 10.


Can you provide the financial health for IMMX stock?

The financial health rating of IMMIX BIOPHARMA INC (IMMX) is 5 / 10.